Two leading cancer centers join effort to securely share genomic, imaging and clinical data to better understand the root causes of cancer and accelerate potentially lifesaving discoveries
The Knight Cancer Institute at Oregon Health & Science University and Intel Corporation are expanding participation in the Collaborative Cancer Cloud, a distributed precision medicine analytics platform, to include Dana-Farber Cancer Institute and Ontario
Institute for Cancer Research. The institutions will join the OHSU Knight Cancer Institute in leveraging Intel’s technology to securely share and analyze their collectively large amounts of data, while preserving the privacy and security of patient
data at each site.
The Collaborative Cancer Cloud combines Intel technologies and bioscience advancements to enable solutions that make it easier, faster and more affordable for developers, researchers and clinicians to determine how hundreds, even thousands of genes interact
to drive disease in individual patients. The cancer cloud is designed to scale to unprecedented volumes of data and allows for secure, aggregated computation across distributed sites without loss of local control of the data, ensuring an institution’s
ability to maintain proper custody of its datasets and protecting patient privacy and any institutional intellectual property that may result.
Engineers and scientists have come together to form a dynamic, new type of team that is developing novel hardware and software technologies optimized for current precision medicine analytics but engineered for longevity – with inherent flexibility to
work with future computer platforms, data standards and analytics solutions.
The Collaborative Cancer Cloud’s unique technical capabilities are what attracted the two research institutions to join the collaboration.
“Through Dana-Farber’s ‘Profile’ project, we have created one of the world’s largest databases of genetic abnormalities that drive cancer, with over 15,000
genetic profiles of patients' tumors, adding about 400 each month to the database,” said Barrett Rollins, MD, PhD, chief scientific officer, Dana-Farber Cancer Institute. “We are excited to be part of
the Collaborative Cancer Cloud and are convinced that the innovative data sharing structure developed by Intel and our academic partners will accelerate the delivery of better treatments to our patients.”
"To understand the causes of cancer and to develop more effective methods of prevention, detection and treatment, cancer researchers need access to rich molecular and clinical data sets,” said Lincoln Stein, MD, PhD, director of the Informatics and bio-computing
program for the Ontario Institute for Cancer Research, and professor, department of molecular genetics at the University of Toronto. “However the information is often siloed and unmanageably large, rendering it effectively inaccessible. Projects like
the Collaborative Cancer Cloud overcome the barriers to working with these data sets by allowing multiple institutions to pool their data and to provide researchers with the computer power needed to work on the data remotely. We’re very eager to begin
collaborative cancer research with these other leading institutions.” Stein works in conjunction with Paul Boutros, the OICR lead for the CCC project.
OHSU Knight Cancer Institute, Dana-Farber Cancer Institute, and Ontario Institute for Cancer Research together with Intel believe that to better understand complex diseases like cancer, the medical and technology industries must collaborate to make the
growing wealth of insights from analyzing public and private genetic datasets accessible for the patient’s benefit.
The expansion of this shareable cancer-treatment knowledge base promises to help advance cancer research and contribute to improved outcomes for patients around the world.
“The entire research community can benefit from insights revealed in large data cohorts,” said Brian Druker, MD, director of the OHSU Knight Cancer Institute. “By securely sharing clinical and research data among institutions, while maintaining patient
privacy, our goal is to turn a process that’s agonizing and uncertain for countless patients into a highly tailored, one-day diagnosis and treatment recommendation.“
Together with Intel Corporation, the three cancer institutions will initially focus on developing genomic pilot projects based on leading industry-standard tools, and will identify novel analytics approaches using machine learning techniques against a
collective set of molecular and imaging data in order to support big data analytics in a federated, aligned environment.
“The end goal is to empower researchers and doctors to help patients receive a diagnosis based on their genome and arm clinicians with the data needed for a targeted treatment plan. By 2020, we envision this happening in 24 hours — ‘All in One Day,’”
said Eric Dishman, vice president and general manager, Health and Life Sciences Group, Intel. “We are honored to bring Intel technology to the Collaborative Cancer Cloud and advance the processing, storage, networking, data security and advanced analytics
necessary to push the boundaries of precision medicine and bring us closer than ever to truly making care personal.”
Long term, OHSU and Intel aim to open this federated, secure Collaborative Cancer Cloud platform to dozens of other institutions, accelerating the ability of clinicians and researchers around the world to understand the root causes of cancer and develop
targeted, molecular treatments. In the future, these underlying technologies may be applied to cardiovascular diseases and neurological disorders, among others, to accelerate scientific discovery, yield new insights and inform treatment plans. A long-term
goal of the collaboration is to reduce “big data” barriers and help make precision medicine widely available to patients.